Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $78.5556.

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $78.64, for a total value of $786,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $55,733,662.16. This represents a 1.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 49,398 shares of company stock valued at $3,650,592 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Root Financial Partners LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth approximately $25,000. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC lifted its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. Richardson Financial Services Inc. boosted its stake in shares of Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 198 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $32,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.5%

Halozyme Therapeutics stock opened at $70.64 on Tuesday. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 28.37, a price-to-earnings-growth ratio of 0.29 and a beta of 0.97. Halozyme Therapeutics has a 1 year low of $47.50 and a 1 year high of $82.22. The firm’s 50 day moving average price is $72.29 and its two-hundred day moving average price is $70.54. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business’s revenue was up 51.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 earnings per share. On average, research analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.